Key Data Updates in MF and AML from ASH 2023

home / data-dialogue-with-the-oncology-brothers / key-data-updates-in-mf-and-aml-from-ash-2023

Following ASH 2023, Uma Borate, MBBS, joins the Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, to discuss key clinical trial data updates in myelofibrosis and acute myeloid leukemia.

Rohit Gosain, MD; Rahul Gosain, MD; and Uma Borate, MBBS, presenting slides

EP. 1: TRANSFORM-1: Navitoclax and Ruxolitinib in Untreated Myelofibrosis

Rohit Gosain, MD;Rahul Gosain, MD;Uma Borate, MBBS
January 17th 2024

Following ASH 2023, Uma Borate, MBBS, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss results from the TRANSFORM-1 trial investigating navitoclax plus ruxolitinib in patients with untreated myelofibrosis.

Rohit Gosain, MD; Rahul Gosain, MD; and Uma Borate, MBBS, presenting slides

EP. 2: MANIFEST-2: Pelabresib plus Ruxolitinib in JAK Inhibitor–Naïve Myelofibrosis

Rohit Gosain, MD;Rahul Gosain, MD;Uma Borate, MBBS
January 17th 2024

Uma Borate, MBBS, and the Oncology Brothers provide insights gleaned from the MANIFEST-2 study, a phase 3, randomized, double-blind study on pelabresib plus ruxolitinib for JAK inhibitor treatment–naïve patients with myelofibrosis.

Rohit Gosain, MD; Rahul Gosain, MD; and Uma Borate, MBBS, presenting slides

EP. 3: Revumenib for Patients With Acute Myeloid Leukemia

Rohit Gosain, MD;Rahul Gosain, MD;Uma Borate, MBBS
January 17th 2024

Medical oncologists discuss the results from the SAVE and AUGMENT-101 clinical trials investigating revumenib in patients with acute myeloid leukemia.

Rohit Gosain, MD; Rahul Gosain, MD; and Uma Borate, MBBS, presenting slides

EP. 4: Key Takeaways from ASH 2023 in Myelofibrosis and AML

Rohit Gosain, MD;Rahul Gosain, MD;Uma Borate, MBBS
January 17th 2024

Following their review of updates from clinical trials presented at ASH 2023, the Oncology Brothers provide their key takeaways on recent data in myelofibrosis and acute myeloid leukemia.